EPA + DHA evidence guide
Omega-3 (EPA and DHA): Benefits, Dosage, Forms and Evidence
Prescription-dose omega-3 reliably lowers high triglycerides.
Prenatal DHA plus EPA probably reduces preterm-birth risk, especially when intake or status is low. Ordinary fish-oil capsules have not consistently prevented heart attacks, cancer, dementia, depression or death. Prescription pure EPA reduced cardiovascular events in one selected high-risk population taking statins. That result does not apply automatically to non-prescription or mixed EPA plus DHA products.1,2,3,4,5,6,7,8,18,19
Moderate
Updated August 1, 202630 min readHuman evidence first
At a glance
Omega-3
- Best-established effect
- Lower triglycerides at a 4 g per day prescription dose2,4,16,17StrongFinding: established use
- Cardiovascular events
- Benefit is limited to prescription pure EPA in eligible high-risk patients2,3,5,6,8,9StrongFinding: benefit supported
- Pregnancy
- Preterm-birth benefit is most plausible when DHA intake or status is low18,19,20,21,22ModerateFinding: small benefit
- Routine healthy-adult use
- No proven reduction in broad cardiovascular events, cancer, dementia or mortality7,8,26,27,28StrongFinding: no meaningful benefit
- Main high-dose caution
- Atrial fibrillation; absolute risk depends on baseline cardiovascular risk5,6,10,14,16,17ModerateFinding: established use
- Best non-fish source
- Algal DHA or algal EPA+DHA; clinical superiority is unproven1ModerateFinding: established use
- Label check
- Combined EPA+DHA per serving, not the larger total-oil number1StrongFinding: established use
Study findings describe groups, not a guaranteed result for one person.
Research and writing
LongevityMate Editorial Team
Editorial oversight
Lukas Dvorsky, FounderClinical review
Not yet assigned or claimed
Popular claims, checked
What supplement influencers are saying
These claims are included because people encounter them. Follower count, a podcast opinion and a personal routine are not scientific proof.
What is claimed
Evidence check
Exaggerated. EPA-dominant products may have a small adjunct effect in some adults with diagnosed depression, but certainty is very low, no universal 1 g threshold is established, and no SSRI non-inferiority evidence supports replacement or dose reduction without the prescriber.
What is claimed
Evidence check
Uncertain and responsibly framed. Mineral oil worsened several biomarkers and the magnitude of any event harm cannot be quantified. Current guidelines still support prescription icosapent ethyl for eligible high-risk patients, while explicitly refusing to generalize it to OTC or mixed EPA+DHA.
What is claimed
Evidence check
Exaggerated as an outcome target. The index is a useful exposure biomarker and observational cohorts find associations, but residual confounding remains. High achieved EPA/DHA in STRENGTH did not predict event benefit, and 8β11% is not an RCT-proven longevity treatment target.
What is claimed
Evidence check
Supported with important caveats. The overall pregnancy evidence favors fewer preterm births, and ADORE's stronger signal was in low-status participants; ORIP was not statistically significant overall. This supports maternity-led targeting, not universal 1 g dosing or guaranteed child benefit.
What is claimed
Evidence check
Exaggerated. Therapeutic doses lower triglycerides and a dietary gap can be corrected, but symptoms do not diagnose deficiency and routine fish oil has not consistently prevented major cardiovascular events, cancer, dementia or death. Higher doses add atrial-fibrillation risk in high-risk populations.
What is claimed
Evidence check
Exaggerated. Oxidation quality matters and market surveys vary, but a human oxidized-oil trial did not show the claimed inflammatory harm. No outcome evidence establishes that most fish oil is toxic or that krill prevents disease more effectively or safely.
Anecdote can start a questionβnot answer it
A personal experience cannot show whether the supplement caused the change, how often it works or whether it is safe for someone else.